Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2008, after the market closes on Wednesday, April 30, 2008.
Conference Call
Sciele will also host a conference call on Wednesday, April 30, beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Analysts, investors and other interested parties are invited to participate by visiting the Company's website, http://www.sciele.com, and entering the Investor Relations page. You may also dial in to listen to the conference call. The dial-in numbers are (888) 668-1645 for domestic callers and (913) 312-0946 international callers. All callers should use passcode 7933154 to gain access to the conference call. Please plan to dial-in or log on at least ten minutes prior to the designated start time so management can begin promptly.
Replay
A seven-day telephonic replay of this conference call will be available by dialing (888) 203-1112 for domestic callers and (719) 457-0820 for international callers. Callers should use the passcode 7933154 to gain access to the replay, which will be available through the end of the day on May 7, 2008. The webcast replay will be available on the Investor Relations page of the Company's website for seven days.
Sciele Pharma, Inc. Background
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit and hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 900 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform – an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork.
Sciele Pharma, Inc.
Joseph T. Schepers, 678-341-1401
ir@sciele.com
